Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients
| Autor: | Arya W. Namin, Robert P. Zitsch, Georgeanne E. Cornell, Lori A. Thombs |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Skin Neoplasms Kaplan-Meier Estimate Disease Risk Assessment Disease-Free Survival Cohort Studies 03 medical and health sciences 0302 clinical medicine 0502 economics and business Humans Medicine Neoplasm Invasiveness In patient Head and neck Melanoma Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Analysis of Variance Retrospective review Sentinel Lymph Node Biopsy business.industry 05 social sciences Middle Aged Prognosis medicine.disease Combined Modality Therapy Survival Analysis United States Surgery Treatment Outcome Otorhinolaryngology Recurrent Melanoma Head and Neck Neoplasms Curative treatment 030220 oncology & carcinogenesis Retreatment Cutaneous melanoma Female 050211 marketing Neoplasm Recurrence Local business |
| Zdroj: | Head & Neck. 41:1304-1311 |
| ISSN: | 1097-0347 1043-3074 |
| DOI: | 10.1002/hed.25562 |
| Popis: | Background The objective of this study was to determine survival outcomes in patients who underwent retreatment of recurrent cases of cutaneous melanoma of the head and neck (CMHN). Methods Retrospective review of all patients who were treated for primary clinical stage I or II CMHN between January 1, 2000 and December 31, 2015. Results Twenty percent (33/168) of the patients developed a recurrence. Sixty-six percent (4/6) of patients who developed local recurrence first and 50% (3/6) of patients who developed regional recurrence first were alive without evidence (NED) of disease at last follow-up, while 0% (0/21) of patients who developed distant or simultaneous recurrences first were NED at last follow-up. Among the 7 patients who were NED, the mean time from recurrence to last follow-up was 735 days. Conclusions Of patients with isolated local or regional recurrences, 58% (7/12) obtained durable curative treatment for recurrent melanoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text